By Jagjagran | 3 October 2026
A major shake-up in global pharmaceutical trade took effect this week — and for India, the news is largely a relief. On 29 September 2026, the United States imposed steep 100% tariffs on patented, branded drugs. But crucially, India's biggest export to the US — generic medicines — remains exempt.
Here's what it means.
WHAT CHANGED
From 29 September, the US extended its Section 232 tariffs to cover patented pharmaceuticals and their ingredients from all companies not already covered.
The rates:
→ 100% baseline tariff on patented/branded drugs
→ 20% for companies with approved US manufacturing plans
→ 0% for companies with special pricing deals (all 17 of the largest manufacturers signed these)
THE GOOD NEWS FOR INDIA
This is where it matters for India, the "pharmacy of the world."
→ Generic medicines and their ingredients remain EXEMPT. Generics are the backbone of India's pharma exports to the US, so the core of the business is protected.
→ Select specialty medicines from India and 19 other countries get 0% duty. These include rare-disease drugs, fertility therapies, and cell and gene therapies.
WHY INDIA'S PHARMA INDUSTRY MATTERS
India is one of the world's largest suppliers of affordable generic drugs, and the US is a huge market. A tariff on generics would have been a serious blow to Indian pharma companies and could have raised medicine prices for millions of American patients.
By keeping generics exempt, the US has, for now, protected both Indian exporters and its own consumers.
THE RISK AHEAD
There is a catch to watch. The US order requires officials to report within a year on whether generics should ALSO face tariffs in future. A phased generics tariff has been floated politically, though nothing is binding yet.
So while Indian pharma can breathe easy today, the industry will be watching Washington closely in the months ahead.
THE BOTTOM LINE
The US has drawn a clear line: expensive branded drugs face steep tariffs, but affordable generics — India's specialty — are spared. It's a win for Indian pharma and for affordable medicine, at least for now.
FREQUENTLY ASKED QUESTIONS
Q: What are the new US pharma tariffs?
A: 100% on patented/branded drugs from 29 September 2026, with lower rates for companies meeting certain conditions.
Q: Are Indian generic drugs affected?
A: No. Generic medicines and their ingredients remain exempt.
Q: Could generics be taxed later?
A: Possibly. US officials must review within a year whether to extend tariffs to generics.
Sources: US Commerce Department, The Tribune, Business Standard, ANI, Open Magazine.
Comments
Post a Comment